

ASX Announcement

Results of Extraordinary General Meeting

Sydney, Australia, 28 September 2023: Imugene Limited (ASX:IMU) (Imugene, or the Company) is pleased to announce the results of today's Extraordinary General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporation's Act.

All resolutions were passed and decided by way of a poll.

Release approved by the Company Secretary on behalf of the Board.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited
View us on YouTube @Imugene Limited



About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Disclosure of Proxy Votes

Imugene Limited

Extraordinary General Meeting

Thursday, 28 September 2023



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Ratification of prior issue of Placement Shares to Placement Subscribers	P	545,287,050	455,039,818 83.45%	81,513,585 14.95%	20,512,356	8,733,647 1.60%	484,604,099 85.60%	81,518,585 14.40%	20,512,356	Passed
2a Approval to issue Placement Shares to Director – Ms Leslie Chong	P	1,062,474,163	974,327,162 91.70%	79,377,334 7.47%	1,035,878	8,769,667 0.83%	1,003,891,443 92.67%	79,382,334 7.33%	1,035,878	Passed
2b Approval to issue New Options to Director – Ms Leslie Chong	P	1,062,474,163	894,211,099 84.16%	159,493,397 15.01%	1,035,878	8,769,667 0.83%	923,775,380 85.28%	159,498,397 14.72%	1,035,878	Passed
3a Approval to issue Placement Shares to Director – Mr Jens Eckstein	P	1,061,737,127	972,717,165 91.62%	79,918,124 7.53%	1,772,914	9,101,838 0.86%	981,781,446 92.47%	79,923,124 7.53%	22,272,914	Passed
3b Approval to issue New Options to Director – Mr Jens Eckstein	P	1,061,767,993	892,854,355 84.09%	159,811,800 15.05%	1,742,048	9,101,838 0.86%	901,918,636 84.95%	159,816,800 15.05%	22,242,048	Passed
4a Approval to issue Placement Shares to Director – Dr Lesley Russell	P	1,061,239,653	971,225,510 91.52%	80,912,305 7.62%	2,270,388	9,101,838 0.86%	1,000,789,791 92.52%	80,917,305 7.48%	2,270,388	Passed
4b Approval to issue New Options to Director – Dr Lesley Russell	P	1,061,260,519	892,111,014 84.06%	160,047,667 15.08%	2,249,522	9,101,838 0.86%	921,675,295 85.20%	160,052,667 14.80%	2,249,522	Passed
5a Approval to issue Placement Shares to Director – Mr Jakob Dupont	P	1,061,888,019	973,217,713 91.65%	79,438,330 7.48%	1,622,022	9,231,976 0.87%	1,002,781,994 92.66%	79,443,330 7.34%	1,622,022	Passed



			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
5b Approval to issue New Options to Director – Mr Jakob Dupont	P	1,061,898,019	892,853,018 84.08%	159,813,025 15.05%	1,612,022	9,231,976 0.87%	922,417,299 85.23%	159,818,025 14.77%	1,612,022	Passed
6a Approval to issue Placement Shares to Director – Mr Paul Hopper	P	1,059,552,569	960,914,658 90.69%	89,535,961 8.45%	3,957,472	9,101,950 0.86%	989,241,797 91.59%	90,778,103 8.41%	3,957,472	Passed
6b Approval to issue New Options to Director – Mr Paul Hopper	P	1,059,521,703	881,734,061 83.22%	168,685,692 15.92%	3,988,338	9,101,950 0.86%	910,061,200 84.27%	169,927,834 15.73%	3,988,338	Passed
7a Approval to issue Placement Shares to Director – Ms Kim Drapkin	P	1,061,867,153	972,711,951 91.60%	79,923,226 7.53%	1,642,888	9,231,976 0.87%	1,002,276,232 92.61%	79,928,226 7.39%	1,642,888	Passed
7b Approval to issue New Options to Director – Ms Kim Drapkin	P	1,061,898,019	892,605,251 84.06%	160,060,792 15.07%	1,612,022	9,231,976 0.87%	922,169,532 85.21%	160,065,792 14.79%	1,612,022	Passed
8 Approval to issue New Options to Sophisticated Investors and Eligible Shareholders	P	1,035,290,926	906,581,524 87.57%	120,095,300 11.60%	20,859,113	8,614,102 0.83%	936,145,805 88.63%	120,100,300 11.37%	20,859,113	Passed

